ORGANIC
LETTERS
1999
Vol. 1, No. 12
1949-1952
Reversal of Regioselection in the
Sharpless Asymmetric
Aminohydroxylation of Aryl Ester
Substrates
Adam J. Morgan,† Craig E. Masse,‡ and James S. Panek*
Department of Chemistry, Metcalf Center for Science and Engineering,
Boston UniVersity, Boston, Massachusetts 02215
Received September 28, 1999
ABSTRACT
The asymmetric synthesis of â-hydroxy-r-amino acids is reported which relies on the use of r,â-unsaturated aryl ester substrates and the
dihydroquinyl alkaloid ligand system (DHQ)2-AQN to control the regio- and enantioselectivity of the asymmetric aminohydroxylation (AA)
process. r,â-Unsaturated ester substrates of type 1 have a significant effect on the substrate−ligand recognition event which results in a
reversal of regioselectivity in the AA reaction.
â-Hydroxy-R-amino acid derivatives frequently occur as
constituents of biologically active peptides, precursors to
â-lactam antibiotics, and synthons for the preparation of
several neurologically active natural products. For instance,
3-hydroxyleucine and 3-hydroxylysine derivatives have at-
tracted considerable attention as unusual amino acid com-
ponents of numerous peptide antibiotics such as azinothricin,1
telomycin,2 lysobacin,3 and the protein kinase C inhibitor
(-)-balanol (Figure 1).4 More recently, 3-hydroxyleucine has
been sought after as a key synthon in the synthesis of (+)-
lactacystin and its analogues (Figure 1).5
In conjunction with our efforts toward the total synthesis
of (+)-lactacystin,5a we began to explore the asymmetric
aminohydroxylation (AA) reaction as an efficient method
to access the hydroxyleucine synthon. Numerous approaches
to the 3-hydroxyleucine have been reported. However, they
lack the flexibility to prepare stereoisomers, require the
preparation of a chiral catalyst system, or are prohibitively
lengthy and not practical for large scale preparations.6 In
our report on the synthesis of (+)-lactacystin, we discovered
that using the AA reaction on a p-bromophenyl ester olefinic
substrate provided the hydroxyleucine synthon with useful
† Recipient of a PREPARE fellowship sponsored by Pfizer Pharmaceu-
ticals.
(5) (a) Panek, J. S.; Masse, C. E. Angew. Chem. Int. Ed. 1999, 38, 1093-
1095. (b) Corey, E. J.; Li, W.; Reichard, G. A. J. Am. Chem Soc. 1998,
120, 2330-2336. (c) Corey, E. J.; Li, W.; Nagamitsu, T. Angew. Chem.
Int. Ed. 1998, 37, 1676-1679. (d) Nagamitsu, T.; Sunazuka, T.; Omura,
S.; Sprengler, P. A.; Smith, A. B. III. J. Am. Chem. Soc. 1996, 118, 3584-
3590.
(6) (a) Horikawa, H.; Petersen, J. B.; Corey, E. J. Tetrahedron Lett. 1999,
3843-3846. (b) Sunazuka, T.; Nagamitsu, T.; Tanaka, H.; Omura, S.;
Sprengler, P. A.; Smith, A. B. III. Tetrahedron Lett. 1993, 28, 4447-4448.
(c) Corey, E. J.; Lee, D.-H.; Choi, S. Tetrahedron Lett. 1992, 33, 6735-
6738. (d) Caldwell, C. G.; Bundy, S. S. Synthesis 1990, 34-36. (e) Jung,
M. E.; Jung, Y. H. Tetrahedron Lett. 1989, 30, 6636-6640. (f) Evans, D.
A.; Sjogren, E. B.; Weber, A. E.; Conn, R. E. Tetrahedron Lett. 1987, 28,
39-43.
‡ Recipient of a Graduate Fellowship from the Medicinal Chemistry
Division of the American Chemical Society 1998-1999, sponsored by
Hoechst Marion Roussel.
(1) Maehr, H.; Liu, C.-M.; Palleroni, N. J.; Smallheer, J.; Todan, L.;
Williams, T. H.; Blount, J. F. J. Antibiot. 1986, 39, 17-21.
(2) Sheehan, J. C.; Maeda, K.; Sen, A. K.; Stock, J. A. J. Am. Chem.
Soc. 1962, 84, 1303-1305.
(3) Tymiak, A. A.; McCormick, T. J.; Unger, S. E. J. Org. Chem. 1989,
54, 1149-1157.
(4) Kulanthaivel, P.; Hallock, Y. F.; Boros, C.; Hamilton, S. M.; Janzen,
W. P.; Ballas, L. M.; Loomis, C. R.; Jiang, J. B. J. Am. Chem. Soc. 1995,
115, 6452-6453.
10.1021/ol9903032 CCC: $18.00 © 1999 American Chemical Society
Published on Web 11/10/1999